A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Pretomanid (Primary)
- Indications Tuberculosis
- Focus Pharmacokinetics
- 09 Oct 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov
- 02 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 04 Sep 2015 Study design has been changed from parallel group to sequential study group.